AGN:NYSE (Ireland) Also trade in: Germany Mexico

Allergan PLC

$ 139.66 0 (0%)
Volume: 1,847,437 Avg Vol (1m): 2,632,614
Market Cap $: 46.12 Bil Enterprise Value $: 68.03 Bil
P/E (TTM): 0.00 P/B: 0.74
Earnings Power Value 8.16
Net Current Asset Value -89.53
Tangible Book -72.62
Projected FCF 241.47
Median P/S Value 126.48
Graham Number 0
Peter Lynch Value -107.27
DCF (FCF Based) 0
DCF (Earnings Based) 0
YTD (-%)

Financial Strength : 5/10

Current vs industry vs history
Cash-to-Debt 0.08
Equity-to-Asset 0.64
Debt-to-Equity 0.37
Debt-to-EBITDA 29.64
Interest Coverage 0.28
Piotroski F-Score 3
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 0.84
DISTRESS
GREY
SAFE
Beneish M-Score -2.64
Not Manipulator
Manipulator
WACC vs ROIC %
ROIC 0.2%
WACC 7.3%

Profitability & Growth : 3/10

Current vs industry vs history
Operating Margin % 1.62
Net Margin % -32.28
ROE % -7.28
ROA % -4.65
ROC (Joel Greenblatt) % -335.54
3-Year Total Revenue Growth Rate 1.60
3-Year Total EBITDA Growth Rate -33.70
N/A
3-Year EPS w/o NRI Growth Rate -20.90
N/A

» AGN's 30-Y Financials

Financials (Next Earnings Date: 2019-05-07)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NYSE:AGN

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS : 325412    SIC : 2834
Compare XTER:MRK NYSE:ZTS SHSE:600276 TSE:4502 NAS:MYL TSE:4523 NSE:SUNPHARMA SHSE:600518 NYSE:TEVA TSE:4507 SZSE:000538 SHSE:600196 XPAR:IPN OCSE:LUN NYSE:PRGO TSE:4508 SZSE:000963 XSWX:VIFN SZSE:300122 JSE:APN
Traded in other countries A60.Germany AGN N.Mexico
Address Clonshaugh Business and Technology Park, Coolock, Dublin, IRL, D17E400
Allergan is one of the largest specialty pharmaceutical manufacturers. It specializes in aesthetics, ophthalmology, women's health, gastrointestinal, and central nervous system products. In 2016, Allergan sold its generics and distribution segments to Teva.

Ratios

Current vs industry vs history
Forward PE Ratio 8.69
N/A
PB Ratio 0.74
PS Ratio 2.99
Price-to-Free-Cash-Flow 8.75
Price-to-Operating-Cash-Flow 8.34
EV-to-EBIT -11.44
EV-to-EBITDA 84.72
EV-to-Revenue 4.32
Shiller PE Ratio 98.64
Current Ratio 1.13
Quick Ratio 0.98
Days Inventory 150.47
Days Sales Outstanding 66.31
Days Payable 58.26

Dividend & Buy Back

Current vs industry vs history
Dividend Yield % 2.05
Forward Dividend Yield % 2.08
N/A
Yield-on-Cost (5-Year) % 2.05
3-Year Share Buyback Rate 5.10

Valuation & Return

Current vs industry vs history
Price-to-Projected-FCF 0.58
Price-to-Median-PS-Value 1.10
Earnings Yield (Joel Greenblatt) % -8.73
Forward Rate of Return (Yacktman) % 14.07

More Statistics

Revenue (TTM) (Mil) $ 15,787.4
EPS (TTM) $ -15.32
Beta 1.6
Volatility % 31.92
52-Week Range $ 125.84 - 197
Shares Outstanding (Mil) 330.22

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 3
Positive ROA N
Positive CFROA Y
Higher ROA yoy N
CFROA > ROA Y
Lower Leverage yoy N
Higher Current Ratio yoy N
Less Shares Outstanding yoy N
Higher Gross Margin yoy N
Higher Asset Turnover yoy Y